13 Approved Bispecific Antibodies Used in Cancer Treatment
Roots Analysis reports on 13 approved bispecific antibodies utilized in cancer and other disease treatments. These novel antibody formats have gained significant traction within the pharmaceutical industry.
Market research firm Roots Analysis has published a report detailing approved bispecific antibodies for the treatment of cancer and other indications. A total of 13 such antibodies have received marketing authorization, highlighting the growing significance of this therapeutic modality.
Bispecific antibodies can bind to two distinct antigens simultaneously. Their application in cancer therapy often involves redirecting immune cells to eliminate cancer cells. Advances in antibody engineering have led to the development of new formats, with approvals escalating, particularly since 2022.
To date, 13 bispecific antibodies have been launched, including Elrexfio™, Talvey™, Epkinly™, Columvi™, and Cadonilimab, which received approval in 2023. Other previously approved therapies include Tecvayli™, Vabysmo™, and Lunsumio™.
Roots Analysis's report analyzes over 400 bispecific antibodies currently under development by more than 155 companies. The study covers the existing market landscape and future opportunities for developers in this field.